Fewer than 20 genomic medicines have been approved so far. Together, they target <0.1% of genetic disorders. 80% of marketed products treat rare diseases.
Emerging waves: the authors anticipate three waves of genomic medicines driven by therapeutic tractability of different diseases and advances in targeted delivery
The authors of this essay recount some of Janssen’s drug development and management wisdom, straying away from the emphasis on hierarchical management governing decisions back to the individual researcher—a system they claim leads to more breakthrough research
‘Act as if your own money were at stake’
Democratization of synthetic biology and machine learning tools, in combination with contract manufacturing organizations, make it much easier for anyone to design potential bioweapons
One domain binds to the disease-relevant protein of interest, while the other domain interacts with the E3 ligase. Here is a great overview of PROTAC technology:
it will take a full stack ecosystem to reduce biothreat risk significantly.